EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access

Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer

Arthur Peyrottes, Michael Baboudjian, Thibaut Long-Depaquit, Morgan Rouprêt, Thierry Roumeguere, Alexandre Peltier, Guillaume Ploussard, Romain Diamand, iTNM Consortium

JAMA Network Open · 15.07.2026 · 9 (7) · e2623288

DOI: 10.1001/jamanetworkopen.2026.23288 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 15.07.2026. Verfasst von Arthur Peyrottes und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Staging, Magnetic Resonance Imaging, Digital Rectal Examination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Magnetic resonance imaging (MRI) is increasingly used for local staging in prostate cancer, yet its value relative to digital rectal examination (DRE) staging remains uncertain.

Objectives

To compare the performance of MRI-based vs DRE-based clinical T staging in men undergoing radical prostatectomy (RP) and to assess the outcome of substituting MRI staging in established prognostic classification systems. Design, Setting, and Participants This multicenter, retrospective case-control study (iTNM Consortium) was conducted from January 1, 2015, to December 31, 2021, among consecutive men 18 years or older with clinically localized or locally advanced prostate cancer who underwent RP and preoperative multiparametric MRI and systematic biopsies with or without targeted biopsies at 31 referral centers across 6 European countries. Patients receiving prior prostate cancer treatment or missing key variables were excluded. Data analysis was performed from August to October 2025. Exposures MRI-derived T stage (iT) vs DRE-derived T stage (cT) incorporated into D’Amico, European Association of Urology, National Comprehensive Cancer Network, and International Staging Collaboration for Prostate Cancer risk groups to generate MRI-adapted classification systems. Main Outcomes and Measures Primary outcome was distant metastasis–free survival. Secondary outcomes were biochemical recurrence–free survival and overall survival. Discrimination was assessed using a C index and time-dependent area under the receiver operating characteristic curves.

Results

A total of 4425 men were included (median [IQR] age, 66 [61-70] years; median [IQR] prostate-specific antigen, 7.4 [5.5-10.5] ng/mL). Median (95% CI) follow-up was 52 (51-53) months. MRI-based staging showed slightly higher discriminatory ability than DRE staging for biochemical recurrence–free survival (C index, 0.62 [95% CI, 0.61-0.64] vs 0.59 [95% CI, 0.57-0.61]) and distant metastasis–free survival (0.67 [95% CI, 0.64-0.70] vs 0.65 [95% CI, 0.62-0.68]). However, across all 4 risk classification systems, MRI-based and DRE-based versions demonstrated comparable discrimination with overlapping 95% CIs. Time-dependent area under the receiver operating characteristic curves showed no significant difference during follow-up. Subgroup analyses of patients with cT1 disease and those with PSA levels less than 10 ng/mL yielded similar results. Conclusions and Relevance In this case-control study of patients undergoing radical prostatectomy, MRI-based staging demonstrated discrimination similar to traditional DRE-based staging for biochemical recurrence, distant metastasis, and overall survival. These findings suggested that MRI-derived staging could be safely integrated into contemporary risk systems without compromising accuracy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm StagingMagnetic Resonance ImagingDigital Rectal ExaminationMaleHumansRetrospective StudiesAgedMiddle AgedCase-Control StudiesProstatectomyPrognosis

Autor:innen und Institutionen

  • Department of Urology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
  • Department of Urology, North Hospital, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, French National Centre for Scientific Research, Interdisciplinary Nanoscience Center of Marseille, ERL INSERM U…
  • Department of Urology, Saint-Anne Instruction Hospital, Service de Santé des Armées, Toulon, France.
  • Groupe Recherche Clinique 5 Predictive Onco-Urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
  • Department of Urology, Jules Bordet Institute-Erasme Hospital, Brussels University Hospital, Brussels, Belgium.
  • Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.

Zitieren

APA

Peyrottes, A., Baboudjian, M., Long-Depaquit, T., Rouprêt, M., Roumeguere, T., Peltier, A., Ploussard, G., Diamand, R., & iTNM Consortium (2026). Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer. JAMA Network Open, 9(7), e2623288. https://doi.org/10.1001/jamanetworkopen.2026.23288

Vancouver

Peyrottes A, Baboudjian M, Long-Depaquit T, Rouprêt M, Roumeguere T, Peltier A, et al. Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer. JAMA Network Open. 2026;9(7):e2623288. doi:10.1001/jamanetworkopen.2026.23288

BibTeX
@article{Peyrottes2026,
  author = {Peyrottes, Arthur and Baboudjian, Michael and Long-Depaquit, Thibaut and Rouprêt, Morgan and Roumeguere, Thierry and Peltier, Alexandre and Ploussard, Guillaume and Diamand, Romain and iTNM Consortium, iTNM Consortium},
  title = {Performance of MRI-Based vs Clinical T Staging in Localized Prostate Cancer},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {7},
  pages = {e2623288},
  doi = {10.1001/jamanetworkopen.2026.23288}
}
Kostenlos starten →